Toripalimab and axitinib
Phase 2Small molecule
Toripalimab and axitinib is one of 7 small molecule programs targeting Preoperative. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Preoperative
#DrugCompanyPhaseTrials
1Neurontin
VViatris Specialty LLC
Approved
Gleevec
NovartisPhase 3
Flagyl
DDePuy Orthopaedics
Phase 2
Inderal
WWyeth-Lederle Vaccines
Phase 2
Anlotinib Hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
Zanaflex
LLegacy Health System
Preclinical
Toripalimab and axitinib
TTianjin Medical University Second Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Toripalimab and axitinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details